Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: felzartamab in adults with IgA nephropathy
2024-519345-30-00Phase 3Authorised
- Sponsor
- Biogen
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Felzartamab with Placebo (2 arms). Primary endpoint: Percent change from baseline in proteinuria as measured by urine protein:creatinine ratio. Planned start Nov 2025; status: authorised.
02
Drugs
felzartamab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-519345-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519345-30-00.